CD274 and non-small cell lung carcinoma: PD-L1 expression has been shown to impact the response to immunotherapies in several solid cancers such as melanoma and non-small-cell lung cancer, where PD-L1 expression on these tumor cells (i.e., presence of target) was shown to be associated with objective treatment response to PD-1 inhibition [121,122].